WHO Collaborating Centres on Influenza definition

WHO Collaborating Centres on Influenza or “WHO CCs” means influenza laboratories designated by WHO and supported by national authorities to perform certain roles within the WHO GISRS, and which have accepted formal Terms of Reference from WHO. In general, they differ from National Influenza Centres and WHO H5 Reference Laboratories in having global responsibilities and more extensive technical capacities. (Consensus)
Sample 1Sample 2
WHO Collaborating Centres on Influenza or “WHO CCs” means animal or human influenza laboratories designated by WHO and fully supported by national authorities to perform certain roles within the [WHO Network], and which have accepted formal Terms of Reference from WHO. In general, they differ from National Influenza Centres and WHO H5 Reference Laboratories in having global responsibilities and more extensive technical capacities. As of May 2008, WHO CCs included the WHO Collaborating Centres for Reference and Research on Influenza in London, Melbourne and Tokyo, the WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza in Atlanta and the WHO Collaborating Centre for Studies on the Ecology of Influenza in Animals in Memphis.
Sample 1
WHO Collaborating Centres on Influenza or “WHO CCs” means animal or human influenza laboratories designated by WHO and fully supported by national authorities to perform certain roles within the [WHO Network], and which have accepted formal Terms of Reference from WHO. In general, they differ from National Influenza Centres and WHO H5 Reference Laboratories in having global responsibilities and more extensive technical capacities. As of May 2008, WHO CCs included the WHO Collaborating Centres for Reference and Research on Influenza in London, Melbourne and
Sample 1

Examples of WHO Collaborating Centres on Influenza in a sentence

  • However: 4.1.1 National Influenza Centres and Other authorized laboratories in developing and least developed countries may charge a nominal administrative fee to recover the costs of shipping, handling, storage or other direct administrative overheads associated with transferring the PIP biological materials to WHO Collaborating Centres on Influenza and/or H5 Reference Laboratories.

  • Haemagglutination inhibition reactions of influenza B (Yamagata lineage) viruses Haemagglution Inhibition Titre1Post infection ferret antisera Genetic Clade 1 < = <10; ND = Not done2 E, egg; MDCK cellsAnnex 1 Declarations of interest The WHO recommendation on composition of influenza vaccines for the southern hemisphere 2014 was made through a technical consultation with relevant WHO Collaborating Centres on Influenza (CCs) and WHO Essential Regulatory Laboratories (ERLs).

  • Provision of diagnostic reagents and test kits (Section 6.4) 6.4.1 WHO Collaborating Centres on Influenza, WHO H5 Reference Laboratories and Essential Regulatory Laboratories, working with the WHO Secretariat, will continue to make available to National Influenza Centres and Other authorized laboratories, without charge, supplies of noncommercial diagnostic reagents and test kits for the identification and characterization of clinical specimens of influenza.

Related to WHO Collaborating Centres on Influenza

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Collaboration Technology means all Collaboration Patents and Collaboration Know-How.

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Collaboration has the meaning set forth in Section 2.1.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Collaborative lawyer means a lawyer who represents a party in a collaborative law process.

  • Collaborating physician means the physician who,

  • Licensor Technology means the Licensor Patents, the Licensor Know-How, Licensor Materials, and Non-Patent Rights Controlled by Licensor or its Affiliates embodied in Licensor Know-How or Licensor Materials.

  • Third Party Technology means all Intellectual Property and products owned by third parties and licensed pursuant to Third Party Licenses.

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Collaborative matter means a dispute, transaction, claim, problem, or issue for resolution, including a dispute, claim, or issue in a proceeding, that is described in a collaborative law participation agreement and arises under the family or domestic relations law of this state, including any of the following:

  • Research Use shall have the meaning given in Section 2.2.2 of this Agreement.

  • Collaboration Term has the meaning set forth in Section 2.1(h).

  • Development Site means any parcel or lot on which exists or which is intended for building development other than the following:

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Research Program has the meaning set forth in Section 3.1.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Autism spectrum disorders means any of the pervasive developmental disorders as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, published by the American Psychiatric Association, including autistic disorder, Asperger's disorder and pervasive developmental disorder not otherwise specified.

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Program Technology means Program Know-How and Program Patents.

  • SAP Technology Solution(s means SAP NetWeaver Foundation for Third Party Applications, SAP Business Technology Platform (excluding when used solely as a Connectivity App between an SAP Application and ERP), SAP Signavio Solutions and SAP Process Insights (including any renamed, prior and/or successor versions of any of the foregoing made generally available by SAP if any but excluding when any of the foregoing are used as a User Interface for ERP.